Giuseppe Curigliano, MD, PhD, Chair of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy.
Giuseppe Curigliano, MD, PhD, is the Chair of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, where besides his clinical work, he is a clinician and researcher specializing in early drug development for patients with breast cancer. Dr. Curigliano earned his MD at the Universita’ Cattolica del Sacro Cuore, in Rome, Italy. He holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994). He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). He moved to the European Institute of Oncology in 1999. In 2010 he was appointed Co-Chair of the Division of Medical Oncology. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the European Society of Medical Oncology (ESMO) and the Italian Association of Medical Oncology (AIOM). He is founding member of/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group. He served on the ESMO Faculty or Breast cancer and on the Program Scientific Committee of the St Gallen conference. He serves on the European School of Oncology (ESO) faculty committee. Dr. Curigliano’s research experiences include principle or coinvestigator in several phase I-II clinical trials with biological, cytotoxic and immune-modulator agents in breast cancer and solid tumors. Dr Curigliano’s research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He serves as member of the editorial board of Journal of Clinical Oncology and Annals of Oncology. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Insititute and the European Journal of Cancer.